Advertisement
Canada markets close in 5 hours 37 minutes
  • S&P/TSX

    21,736.06
    +80.01 (+0.37%)
     
  • S&P 500

    5,033.68
    +11.47 (+0.23%)
     
  • DOW

    37,970.08
    +216.77 (+0.57%)
     
  • CAD/USD

    0.7264
    +0.0000 (+0.01%)
     
  • CRUDE OIL

    82.77
    +0.08 (+0.10%)
     
  • Bitcoin CAD

    87,720.63
    +3,099.54 (+3.66%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,398.90
    +10.50 (+0.44%)
     
  • RUSSELL 2000

    1,952.00
    +4.05 (+0.21%)
     
  • 10-Yr Bond

    4.6240
    +0.0390 (+0.85%)
     
  • NASDAQ

    15,696.56
    +13.19 (+0.08%)
     
  • VOLATILITY

    18.06
    -0.15 (-0.82%)
     
  • FTSE

    7,863.43
    +15.44 (+0.20%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6817
    +0.0015 (+0.22%)
     

What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.